Psychedelic Medicine · Suicide Risk · Clinical Consulting
Psychedelic medicine opens doors.
Some patients should not walk through them alone.
Ketamine clinics and psilocybin programs are treating some of the most psychologically complex patients in clinical practice. Suicide risk expertise is not optional in that context — it is foundational.
Psychedelic medicine attracts
high-risk patients by design.
Treatment-resistant depression. Chronic suicidality. Trauma that hasn’t responded to anything else. These are exactly the populations that psychedelic-assisted therapies are being developed to serve — and exactly the populations that require the most rigorous suicide risk assessment and monitoring.
Ketamine clinics, psilocybin programs, and integration practices are operating at the frontier of this field, often without established protocols for evaluating and managing suicide risk before, during, and after treatment. The liability exposure is real. More importantly, so is the clinical need.
Dr. Walsh consults with psychedelic medicine providers on the specific suicide risk challenges their patient populations present — bringing 20 years of clinical expertise in suicidality, crisis assessment, and complex adult psychopathology to a field that needs it.
Current Consulting Areas
- Ketamine — legal, clinical settings
- Psilocybin — Oregon & Colorado programs
- Psychedelic integration — substance-agnostic
- Writing & education on psychedelic medicine
Where suicide risk expertise
meets psychedelic medicine
The clinical challenges are specific and underserved. Most psychedelic medicine training programs cover therapeutic technique. Very few address the complexity of managing active suicidality in patients seeking or undergoing psychedelic treatment.
Pre-treatment suicide risk screening
- Clinical review of screening protocols for suicidality and high-risk presentations
- Guidance on which patients require additional evaluation before proceeding
- Consultation on exclusion criteria and clinical edge cases
- Documentation and informed consent considerations for high-risk patients
Treatment protocol review
- Review of existing protocols for suicide risk monitoring across the treatment arc
- Identification of gaps in crisis response planning before, during, and after sessions
- Recommendations for managing difficult emergent material in session
- Post-treatment monitoring and integration safety planning
Clinical staff training & education
- Education on suicide risk assessment for clinicians working in psychedelic settings
- Training on recognizing and responding to suicidal crisis during and after treatment
- Writing and speaking for professional and organizational audiences
- Available for conference presentations and clinical education programs
Active crisis management during treatment
- Training facilitators to recognize and respond to suicidal crisis emerging during altered states
- Distinguishing treatment-emergent distress from genuine acute risk in session
- De-escalation and containment strategies specific to psychedelic treatment contexts
- When and how to interrupt a session — decision frameworks for facilitators in the room
- Post-session crisis protocols and handoff to appropriate care
Why this combination
of expertise matters now
The patient population is complex
- Ketamine and psilocybin programs disproportionately attract patients with treatment-resistant conditions, chronic suicidality, and significant trauma histories
- Standard intake screening often underestimates risk in patients who are highly motivated to access treatment
- The altered states these treatments produce can intensify psychological material that requires careful clinical management
The field is moving faster than the protocols
- Ketamine clinics are operating now, at scale, with significant variation in clinical rigor
- Psilocybin programs in Oregon and Colorado are live and expanding
- Established suicide risk assessment frameworks have not been systematically adapted for psychedelic medicine contexts
- The regulatory and liability environment is developing in real time
This expertise is rare
- Deep clinical expertise in suicidality is not common in psychedelic medicine training
- Forensic-level understanding of liability and documentation is rarer still
- Dr. Walsh brings both — along with active engagement with the clinical literature on psychedelic medicine and its intersection with psychological risk
How consulting engagements
typically unfold
- Initial conversationA focused call to understand your program, patient population, current protocols, and the specific gaps or concerns you want addressed. No commitment required at this stage.
- Scope definitionConsulting engagements are tailored to what your program actually needs — protocol review, staff training, screening tool evaluation, or ongoing advisory. Scope and fees established before work begins.
- DeliverablesWritten recommendations, training materials, protocol annotations, or clinical consultation — depending on the engagement. All work reflects current clinical evidence and professional standards.
- Ongoing availabilityAvailable for ongoing advisory relationships with programs that want consistent clinical input on complex patient presentations or protocol development over time.
Examples of the kind of work
that fits this practice
Review of intake screening protocols at a ketamine infusion clinic, with recommendations for identifying high-risk patients who require additional psychiatric evaluation before proceeding.
Facilitator training on recognizing and managing active suicidal crisis during psychedelic sessions — decision frameworks for when to intervene, de-escalation strategies, and post-session handoff to appropriate care.
Consultation on documentation and informed consent frameworks for programs treating patients with active or recent suicidal ideation.
Writing and speaking on suicide risk in psychedelic medicine contexts for professional association conferences, clinical training programs, or industry publications.
This is a field that needs
clinical depth.
If you’re running a ketamine clinic, psilocybin program, or integration practice and want to talk through your approach to suicide risk — the conversation starts with a call.